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Abstract
Keratocystic odontogenic tumors (KCOTs) are cystic tumors that arise sporadically or associated with nevoid basal cell
carcinoma syndrome (NBCCS). NBCCS is a rare autosomal dominantly inherited disease mainly characterized by multiple
basal cell carcinomas, KCOTs of the jaws and a variety of other tumors. PTCH1 mutation can be found both in sporadic or
NBCCS associated KCOTs. The aim of the current study was to assess whether a combined clinical and bio-molecular
approach could be suitable for the detection of NBCCS among patients with a diagnosis of keratocystic odontogenic tumors
(KCOTs). The authors collected keratocystic odontogenic tumors recorded in the database of the Pathology Department of
the University of Modena and Reggio Emilia during the period 1991–2011. Through interviews and examinations, family
pedigrees were drawn for all patients affected by these odontogenic lesions. We found out that 18 of the 70 patients with
KCOTs and/or multiple basal cell carcinomas actually met the clinical criteria for the diagnosis of NBCCS. A wide inter- and
intra-familial phenotypic variability was evident in the families. Ameloblastomas (AMLs) were reported in two probands that
are also carriers of the PCTH1 germline mutations. Nine germline mutations in the PTCH1 gene, 5 of them novel, were
evident in 14 tested probands. The clinical evaluation of the keratocystic odontogenic tumors can be used as screening for
the detection of families at risk of NBCCS. Keratocystic odontogenic lesions are uncommon, and their discovery deserves the
search for associated cutaneous basal cell carcinomas and other benign and malignant tumors related to NBCCS.
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Introduction
The odontogenic keratocyst is a cystic lesion that has a putative
growth potential and a propensity for recurrence [1,2]. Although
the great majority of keratocysts occur in isolation as single, non-
syndromic cysts, they may also present as multiple cysts as a feature
of the nevoid basal cell carcinoma syndrome [NBCCS or Gorlin
syndrome-GS, OMIM#109400]. NBCCS is a rare autosomal
dominantly inherited disorder with variable clinical manifesta-
tions, such as basal cell carcinomas of the skin, keratocysts of the
jaws, palmar or plantar pits, ectopic calcifications of the falx
cerebri [3,4]. The estimated birth incidence of the disorder is
approximately 1 per 31,000, ranging from 1 per 19,000 in the
United Kingdom to 1 per 256,000 in Italy to 1 per 235,800 in
Japan [5–7].
Multiple jaw keratocysts are the most consistent and common
manifestation of the syndrome, occurring in 65–100% of patients
[3]. The syndrome-associated keratocysts are found in both jaws
with equal frequency, in contrast to non-syndromic cysts, which
are most frequently associated with the lower jaw [8]. Keratocysts
often represent the first manifestations of NBCCS, frequently
preceding syndromic basal cell carcinomas, thus facilitating early
diagnosis [9].
In 2005, the WHO working Group recognized Odontogenic
keratocysts as tumors and recommended the use of the term
keratocystic odontogenic tumor (KCOT), in order to distinguish
the lesion from the ortho-keratinizing variant, which is considered
as an odontogenic cyst [10]. The histologic diagnosis of KCOTs is
primarily based on the presence of specific microscopic features:
a thin, stratified squamous epithelium with a prominent palisaded
basal layer; a smooth interface with the stroma, lacking rete pegs
and a wavy or corrugated parakeratinized surface layer. Immu-
nohistochemical staining for keratin 10, a low-molecular-weight
cytokeratin that is expressed in a subset of keratinocytes within
normal gingival mucosa, shows a characteristic strong staining of
the superficial parakeratinized cells of KCOTs and can be applied
to both histologic and cytological samples as an ancillary marker to
support the diagnosis of an KCOT [11–13].
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PTCH1 mutation can be found in sporadic or NBCCS
associated KCOTs [8]. The PTCH protein serves as a receptor
for the Secreted Shh (SHH) protein, and inhibits the signaling
pathway by repressing the activity of Smoothened (SMO), another
transmembranous protein [14]. The SHH signaling pathway plays
an important role in mammalian embryonic development of
structures such as the neural tube, axial skeleton, limbs, lungs, skin,
hair follicles, and teeth [15]. SHH signaling also regulates growth
and determines the shape of teeth. [16].
The specific objective of our study was to evaluate whether
a matched clinical and molecular screening could be useful for the
recognition of NBCCS among patients with a diagnosis of
KCOTs.
Results
Among 70 patients affected by KCOTs there were 40 males
and 30 females (ratio 1:1.3 ). Their age ranged from 14 to 86 years
(mean 50.8).
We collected clinical characterization and family history of all
patients. 18 patients had a personal and/or family history of BCCs
and/or other signs and symptoms fulfilling the criteria for
NBCCS. Among these NBCCS probands there were 9 males
and 9 females. The male to female ratio of the NBCCS probands
was 1:1.
BCCs were preferentially located on the scalp in females and on
the lower limbs in males. The face was equally affected in males
and female whereas the trunk was predominantly involved in
males, especially in the lower portion; instead, females showed the
prevalence of BCCs in the upper trunk [Figure 1].
All of the remaining 52 patients were categorized with sporadic
KCOTs tumors. In the NBCCS group, there were approximately
55 KCOTs, including 2 AMLs. The average age at onset of the
first KCOT was 18,8 years compared with 45,5 years in the
sporadic group [Table 1].
The great majority of cysts arise sporadically and in single form
on jaws of middle-aged people. When associated with the NBCCS,
these lesions appear earlier, often during the first or second decade
of life, and they are often multiple, synchronous or metachronous
[Figure 2] [Table 2].
In 10 patients with NBCCS, KCOTs occurred as the first
neoplasm, while they were diagnosed in 8 patients only after the
development of BCCs.
Among the 16 NBCCS probands with diagnosis of basocellular
carcinomas, the number of BCCs varied from a few (patient
number 17) to several thousands (patient number 3) and ranged in
size from 1 to 35 mm in diameter. The average age at onset of the
first BCC was 27,5 years. The remaining one did not show any
BCCs [Figure3].
Although the histopathology of BCCs in NBCCS patients
cannot be differentiated from that of sporadic BCCs, approxi-
mately 30% of patients present two or more histologic sub-types of
BCCs with superficial, nodular, cystic, sclerosing patterns and
fibroepithelioma of Pinkus (patient number 5) [Table 2].
Overall, a wide phenotypic and genotypic variability was
registered, in the spectrum of both skin and odontogenic tumors,
even among members of the same family who had different clinical
manifestations.
In addition to odontogenic and cutaneous tumors, the tumor
spectrum included thymoma, fetal thoracic rhabdomyoma, giant
cells tumors and ovarian fibroma.
The relationship between the development of KCOTs and
other main features of the syndrome (BCCs, brain tumors,
palmar/plantar pits, abnormal ribs, abnormal vertebrae, heart
tumors, and ovarian tumors) was also examined. Probands with
NBCCS who had been affected by KCOTs had a median of three
other features of the syndrome. The most common features were
BCCs (95%), abnormal ribs and vertebrae (23%) and palmar/
plantar pits (11%). Sporadic patients with KCOTs were also
screened for clinical features (i.e. other neoplasms) that are not
associated to NBCCS in order to analyze their potential
associations.
The results of the molecular analysis of 14 consenting Italian
patients with histologically confirmed NBCCS are shown in
Table 2. We found 9 germline PTCH1 mutations (60%) which
appeared to be uniformly distributed across the PTCH1 gene.
Seven of them (77,8%) belonged to patients with family history of
NBCCS. To our knowledge, 5 of them (c.654+2T.A, c.1348-
2a.G, c.585-1G.A, c.931dupA, c.1237C.T [p.Q413X] were
novel and had not been described yet, 2 (c.3277G.A
[p.G1093R], c.2186A.T [p.K729M]) had been recently reported
[17,18] and 2 had already been reported in the literature
(c.1987C.T [p.Q663X], c.2062 C.T [p.Q688X]) [19].
Discussion
A combined clinical and molecular screening could be useful for
the recognition of NBCCS in patients that already have an early
diagnosis of multiple KCOTs, starting with the evaluation of
retrospective pathological records. NBCCS is usually diagnosed
through the detection of multiple BCCs at the skin examination;
our approach chose to guide the discovery of affected patients
starting from another major criteri (KCOTs). The majority of the
KCOTs in this series (74,8%) were sporadic and not associated
with the mutation of PTCH1. These results clearly indicate that
most KCOTs develop as sporadic forms, confirming the
discriminatory role of an accurate family medical history that
should be viewed as the crucial step for a proper diagnosis of
NBCCS. In particular, the case-history can be very helpful in the
diagnosis of the syndrome in young children that only present
KCOTs, but its role is limited to NBCCS patients who are the first
affected in their families. The early recognition of PTCH1 gene
carriers allows the assessment of a strict clinical and instrumental
follow-up, leading to the detection of further tumors such as other
BCCs and KCOTs, as well as medulloblastomas in affected
children,
In this study, approximately 25,6% of KCOTs patients were
associated with the autosomal dominantly inherited NBCCS. Of
these patients, 11 presented multiple KCOTs. In a previous study
the diagnosis of NBCCS was associated with 6% of all KCOTs,
percentage similar to those of other reports, which ranged between
1,4% and 8,2% [20–23]. The higher incidence of NBCCS in
patients with odontogenic cysts can be reasonably explained by
two factors. Firstly, in our study, an accurate family history
(including a detailed recording of radiographic and photographic
pictures), was extended to second, third and fourth degree relatives
(instead of being limited to second-degree relatives). Secondly, all
patients were accurately screened for basal cell carcinomas with
dermoscopy. Dermoscopy is an imaging technique that has been
proven to greatly improve the diagnostic accuracy of BCCs and
other skin tumors compared to naked eye examination. Together,
these aspects can support the higher incidence of NBCCS in our
patients, since previous studies did not explore the entire family
pedigree of the probands; moreover, the diagnosis of BCC was
performed through the clinical examination alone.
BCCs are not constantly associated to KCOTs in patients with
PTCH1 mutation. Normally, the only sign of BCCs not associated
to KCOTs is not enough to allow the suspect of NBCCs, although
Odontogenic Keratocistic as Clue for NBCC Syndrome
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Figure 1. Clinical features of NBCCS’ patients (a, d : patient n. 3; b, e : patient n.16; c: n.11 proband’s’brother; d: n. 11 proband’s
father; see Table 2).
doi:10.1371/journal.pone.0043827.g001
Table 1. Odontogenic tumors in patients with Nevoid Basal cell Carcinoma Syndrom and in patients with sporadic lesions.
NBCCS patients Non syndromic patients
P Value
a,0.05
N patients 18 (25.7%) 52 (74.3%) –
Gender:
Female 9 (12.8%) 21 (30%) –
Male 9 (12.8%) 31 (44.4%) –
KCOTs:
KCOTs per patient (mean 6 SD) 2.962.5 1.460.75 0.0001
KCOTs onset yrs (mean 6 SD) 18.869.2 45.5616.9 0.0014
KCOTs location:
Upper jaw 18 (34.6%) 16 (22%) –
Lower jaw 34 (65.4%) 57 (78%) –
Histology:
KCOTs 52 (41.2%) 73 (58,8%) –
AML 2 (100%) 0 (0%) –
KCOTs: Keratocistic odontogenic tumors;
AML: ameloblastomas;
SD: Standar.
doi:10.1371/journal.pone.0043827.t001
Odontogenic Keratocistic as Clue for NBCC Syndrome
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some patients develop the other requested signs for the clinical
diagnosis of NBCCS (according to Kimonis’s criteria) later [4]
Regarding the body site distribution of BCCs, we found
a prevalence of BCCs on the scalp, and upper extremities in
females (i.e. patient number 1, 13, 16) whereas the back (lower
portion) and lower extremities were preferentially involved in
males (i.e. patient number 3, 4, 7). The face did not show any
difference in term of BCCs distribution. According with previous
data [24], the involvement of the scalp was typically found in
females; however, a different distribution was found for the back
and the extremities. In fact, Winnies et al found a prevalence of
BCCs on the lower extremities and back in females. This could
simply be related to a higher number of patients included in their
study compared to our population.
No firm evidence for a genotype/phenotype correlation in
NBCCS has been demonstrated, and there is adequate variation in
single families to believe that environmental exposure, and
perhaps modifier genes, may justify much of the variation. The
presence or absence of a PTCH1 mutation, mutation type, and
gender have virtually no impact on the onset age of the first BCC
or on the numbers of BCCs developed by the patient. This is
clinically relevant as the finding of a specific PTCH1mutation does
not appear to give prognostic information about the likely age of
onset of BCC or the clinical disease burden. In NBCC Syndrome
patients, neither the age of onset of BCCs or the number of BCCs
that develop can be predicted by the presence or absence of
a PTCH1 mutation or by the type of the mutation [25].
A review of the literature highlights that AML was rarely
associated to NBCCS because it was reported in only a few
patients, confirming that an advanced age may be at a greater risk
of presenting AML in NBCCS [26]. In disagreement with this
reports in our case series two of 18 (11%) patients were affected by
AML (patient number 8 and 14); therefore this tumor could
represent not only an incidental finding but a potential sign of an
hereditary disorder, that might be as useful as KCOTs as
a screening criterion for the identification of PTCH1 gene-carrier
individuals at risk of NBCCS.
AMLs arise from remnants of dental lamina, an embryonic
structure that normally differentiates into tooth buds and enamel-
producing cells during odontogenesis. The dysregulation of the
PTCH1-SHH signaling pathway in the interactions between
epithelium and mesenchyme may induce the formation of the
KCOTs and AMLs.
NBCCS associated Keratocysts and AMLs presumably arise
from precursor cells that contain a hereditary ‘‘first hit’’, and the
allelic loss represents the loss of the normal allele [27,28]. Sporadic
KCOTs and AMLs may arise from susceptible cells in which two
of the somatic ‘‘hits’’ have occurred, one of them manifesting as
allelic loss. The PTCH1 gene may function as a ‘‘gatekeeper gene’’
[29]. Indeed, this model has been proposed whereby inactivation
of a gatekeeper gene is required for passing the genetic threshold of
the neoplastic process in a given tissue. It is possible that cells of
the KCOTs and AMLs, after losing the PTCH1 function, become
targets of other genetic alterations.
The dermatologic features of NBCCS have a significant impact
on affected individuals. Among NBCCs patients presented in this
study the number of BCCs varies from a few to several thousands,
ranges in size from 1 to 30 mm and includes two or more
histologic sub-types of superficial, nodular, pigmented patterns
and fibroepithelioma of Pinkus. This last peculiar dermatological
lesion was recently described by Go JW et al. as one of the several
sub-types of cutaneous BCCs associated with the NBCCS tumor
spectrum [30].
In the current study, molecular characterization showed
a germline PTCH1 mutations in 9 patients [Table 1].
The geno-phenotype characterization in the presented NBCCS
cases shows no correlation between NBCCS specific clinical
features and particular functional domains inside this gene,
together with an ample phenotypic variability. This includes cases
both with a marked familial cancer aggregation and apparently
sporadic, in which the association of KCOTs and BCCs is present
only in single individuals [Table 2]. On the other hand, it seems
rather unclear how, under the same mutation and family history,
a NBCCS phenotype only appears in some cases: for instance, the
same mutation associated to NBCCS phenotype in a patient does
not match with such phenotype in other carriers of the same
mutation, either in the same family [Figure 2] or in other NBCCS
correlated families.
At this regard, we recently reported the missense mutation
c.3277G.C (p.G1093R) in exon 19 of the PTCH1 gene – which
had been previously reported only in non-syndromic KCOTs - in
a familiar case (father and daughter of patient number 1) of classic
NBCCS phenotype [17]. This observation suggests that this
Figure 2. Dental Orthopantomography of a patient affected by NBCCS. (Patient n.11 of table 2).
doi:10.1371/journal.pone.0043827.g002
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missense mutation might take part in the pathogenesis of NBCCS
as well as in a subset of non syndromic KCOTs. These evidences
of the wide inter- and intra-familial phenotypic variability could be
due to lower penetrance of PTCH1 gene and is likely to result from
the action of modifier genes. There is evidence that the
manifestations of many genetic disorders are influenced by so-
called ‘modifying’ genes distinct from the disease locus. Anyway,
the final NBCCS phenotypic outcome might be also modified by
epigenetic factors such as ethnicity and environmental factors:
among these the ultraviolet (UV) light is one of the high-risk
factors for BCC development in NBCCS.
Overall, the multiple and early-onset KCOTs characteristic of
NBCCS can serve as premonitory physical stigmata for an
underlying cancer predisposition: in our opinion, every patient
with a KCOTs (or AMLs) should be further evaluated and, if
necessary, put under strict cancer surveillance. In conclusion, the
current findings indicate a possible strategy that may be followed
for the identification and management of NBCCS patients for
which the early diagnosis of clinical manifestations is crucial
because of the risk of medulloblastoma, ovarian fibroma and other
neoplasms of the NBCCS tumor spectrum.
Materials and Methods
Patients and Tumor Samples
From 1994 to 2011, all keratocystic odontogenic tumors
(embedded in paraffin) belonging to 70 patients were selected
through the examination of the archives of the Pathology
Departments of the Universities of Modena and Napoli.
The hematoxylin and eosin-stained slides were re-evaluated to
confirm the diagnosis according to WHO classification of 1992
[10]. If the final diagnosis could not be made through
histopathologic evaluation alone, clinical and radiographic find-
ings were considered. When the original slides were not
representative or were inadequate, new additional slides were
prepared from paraffin blocks. In case of controversies, another
oral pathologist was consulted in order to ensure that the final
diagnosis was correct.
For purposes of recruitment for this study, criteria used for
diagnosis of NBCC syndrome were the presence of 2 major, or one
major and 2 minor criteria. The major criteria included multiple
BCCs or one BCC before 30 years, keratocysts of the jaw,
palmar/plantar pits and lamellar calcification of the falx cerebri
on skull radiograph. Minor criteria included spina bifida occulta or
other vertebral anomalies, brachymetacarpaly in at least one limb,
hypertelorism or telecanthus, frontal bossing, rib anomalies (bifid,
synostosed, hypoplastic), ovarian fibroma, medulloblastoma, flame
shaped lucencies in the phalanges, and brachymetacarpaly in the 4
limbs. One diagnosis was also established by the presence of a first
degree relative with NBCC and one major or two minor criteria.
[4]. The anatomic distribution of BCCS was recorded according
to six body sites (head and neck, M-face, Scalp, upper extremities,
lower extremities, trunk). All patients were screened for the
presence of BCCs by using a combined clinical-dermoscopic exam
[31].
Family History
Detailed family histories were collected for each patient by
interviewing the patients and/or their relatives. Verification of
cancer occurrence among family members could be obtained in
the majority of patients through clinical charts, pathologic records,
or death certificates. Through the reconstruction of the genealogic
tree, we identified 18 patients with NBCCS.
Mann-Whitney Test (a,0.05) was applied to assess the
probability of KCOTs per patients and and KCOTs onset year,
respectively, in NBCCS patients versus non syndromic patients.
Statistical analysis was performed using GraphPad 5.0 (Prism 5.0,
GraphPad Software, Inc., San Diego, CA).
Mutational Analysis
The peripheral blood samples were collected from the NBCCS
proband and their first-degree relatives. Written informed consent,
agreeing to peripheral blood sampling and genetic analysis, was
Figure 3. Genealogic tree of NBCCs family without the diagnosis of BCCs (Patient n.11 of table 2).
doi:10.1371/journal.pone.0043827.g003
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obtained from each patient enrolled in the study. Molecular
analysis of PTCH1 was performed as previously described [26].
The PTCH1 cDNA sequence from GenBank (Accession number
U59464.1) was used as a reference sequence, where the A of the
ATG translation initiation start site represents nucleotide +1.
An Institutional Review Board (IRB) approval was obtained and
the study was conducted according to the Declaration of Helsinki
Principles. All patients provided their written informed consent for
the management of personal data and for publication of their
photographs before participating into the study.
A council of senior specialists at the same University De-
partment (Prof. Alberto Giannetti, Prof. Anto De Pol and Prof.
Cristina Magnoni) reviewed and approved the study design,
inclusion/exclusion criteria.
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